Regeneron Pharmaceuticals Inc（REGN）股票分析REGNRegeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Lynozyfic, and others. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Regeneron Pharmaceuticals Inc is a good buy right now, trading at $790.74 with a strong forward P/E of 14.51, indicating potential for earnings growth. The recent positive Phase 3 trial results for Pasatru highlight significant efficacy, which could drive future revenue. Additionally, hedge funds have increased their buying activity by 167% over the last quarter, suggesting strong institutional confidence. However, the RSI is at 69.33, indicating that the stock may be nearing overbought territory, which is a risk to consider.

26 analysts cover REGN: 13 rate it Buy, 12 Hold and 1 Sell. The average price target is 808.50.